Figure 2.

An overview of the types of liver diseases that can potentially be treated with cell therapy

The efficiency of engraftment and repopulation of donor cells is dictated by the host tissue microenvironment. The number of donor cells needed to provide therapeutic benefits is dependent on the recipient liver pathophysiology. Shown are pathological features (top row), the intent and targets of cell transplantation-based therapy (center row), and the overall results of the different cell sources used (bottom row). AIH, autoimmune hepatitis; BTSC, biliary tree stem cell; HPC, hepatic progenitor cell; HT, hepatocyte transplantation; MSC, mesenchymal stem cell; NAFLD, non-alcoholic fatty liver disease; OLT, orthotopic liver transplantation.